The continued rise in chronic, often fatal, diseases along with the research and development efforts to treat them is propelling dramatic growth in stem cell banking.
We knew it was coming, and we’ve written about it already, but this morning’s release of their Q1 numbers just confirmed Charles Schwab's (NYSE:SCHW) recovery has begun.